Sex-Based Disparities in Fabry Disease Cause Challenges in Newborn Screening
Public Health Genomics · 21.05.2026 · 29 (1) · 158-168
DOI: 10.1159/000552599 ↗Kurz gefasst
Fachartikel in der Zeitschrift Public Health Genomics, online erschienen am 21.05.2026. Verfasst von Yutaka Furuta und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Medical Genetics and Genomic Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA, yutakaf…. Hauptthemen laut MEDLINE: Fabry Disease, Neonatal Screening. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NICHD NIH HHS.
Abstract (Originalsprache)
Introduction
Fabry disease (FD) is a multi-systemic, X-linked lysosomal storage disorder caused by decreased α-galactosidase activity. Early diagnosis enables timely treatment, but enzyme-based newborn screening (NBS) may not detect affected females. We hypothesized that enzyme-based NBS limitations contribute to sex-based diagnostic disparities in FD and investigated these differences.
Methods
Retrospective cohort analyses used data from the Fabry Registry (FR: 2001–2023) and Tennessee NBS (2017–2024). Sex differences in diagnosis via NBS, biochemical phenotype, symptom onset, and treatment initiation were analyzed using Wilcoxon and chi-square tests.
Results
Among 8,657 FR individuals, 73 (67 males, 6 females) were identified via NBS. FR data show that affected females had significantly higher residual α-galactosidase activity than affected males (leukocyte median: 45.9% vs. 3.9%, plasma median: 32.5% vs. 3.9%; p < 0.0001 for both). FR females had delayed symptom onset (18.1 vs. 11.1 years), later diagnosis (35.5 vs. 30.8 years), and lower treatment rates (51.1% vs. 80.8%) compared to males (all %, p < 0.0001). Tennessee NBS detected 25 males but no females.
Conclusion
Females with FD have delays in symptom onset, diagnosis, and treatment compared to males. Furthermore, higher residual enzyme activity causes current enzyme-based NBS to miss most females. Incorporating sex-specific cutoffs and/or molecular sequencing into NBS could improve early detection and reduce sex-based disparities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Medical Genetics and Genomic Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA, yutakafuruta8@gmail.com.
- Department of Pediatrics, Division of Medical Genetics and Genomic Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Sanofi, Cambridge, Massachusetts, USA.
- Department of Medical Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Förderung
- NICHD NIH HHS
Zitieren
APA
Furuta, Y., Agrawal, N. S., Owen, N. N., Bastarache, L. A., Shyr, C., Geiger, H. U., Ponce, E., Lauderdale, C. J., Carter, C. R., Morgan, K. A., Hamid, R., Phillips Iii, J. A., & Tinker, R. J. (2026). Sex-Based Disparities in Fabry Disease Cause Challenges in Newborn Screening. Public Health Genomics, 29(1), 158-168. https://doi.org/10.1159/000552599
Vancouver
Furuta Y, Agrawal NS, Owen NN, Bastarache LA, Shyr C, Geiger HU, et al. Sex-Based Disparities in Fabry Disease Cause Challenges in Newborn Screening. Public Health Genomics. 2026;29(1):158-168. doi:10.1159/000552599
BibTeX
@article{Furuta2026,
author = {Furuta, Yutaka and Agrawal, Neena S and Owen, Natalie N and Bastarache, Lisa A and Shyr, Cathy and Geiger, Hanabi U and Ponce, Elvira and Lauderdale, Chelsea J and Carter, Camille R and Morgan, Karee A and Hamid, Rizwan and Phillips Iii, John A and Tinker, Rory J},
title = {Sex-Based Disparities in Fabry Disease Cause Challenges in Newborn Screening},
journal = {Public Health Genomics},
year = {2026},
volume = {29},
number = {1},
pages = {158--168},
doi = {10.1159/000552599}
}
EUVIMED